The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center

DOI: https://doi.org/10.1007/s00405-024-08627-8

2024-04-09

European Archives of Oto-Rhino-Laryngology

Abstract:The incidence of salivary duct carcinoma (SDC) seems to be underestimated due to inaccurate classification. Further, the frequency of SDC patients with targeted therapy options according to current guidelines is unclear. Therefore, this study aimed at (a) describing the proportion of SDC among salivary gland carcinoma (SGC) before and after reclassification of cases initially classified as adenocarcinoma, not otherwise specified (ANOS); and (b) quantifying the frequency of SDC patients with targeted therapy options.

otorhinolaryngology

What problem does this paper attempt to address?

This paper attempts to solve the following two main problems:

1. **Describe the proportion of salivary duct carcinoma (SDC) in salivary gland carcinoma (SGC)**:
- How does the proportion of SDC in SGC change before and after re - classification? In particular, for those cases initially classified as adenocarcinoma not otherwise specified (ANOS), how many were identified as SDC after re - classification?
- Has the proportion of SDC increased during the study period?

2. **Quantify the frequency of targeted therapy options in SDC patients**:
- Specifically, in the study, how many SDC patients have androgen receptor (AR) expression in more than 70% of tumor cells, and how many patients are human epidermal growth factor receptor 2 (HER2) - positive?
- According to the current guidelines, does the presence of these molecular markers allow most SDC patients to receive targeted therapy?

### Background and Objectives
Salivary duct carcinoma (SDC) is a rare but highly malignant head - and - neck tumor with a poor prognosis. Due to inaccurate classification, the incidence of SDC may be underestimated. In addition, according to the existing guidelines, the frequency of targeted therapy options in SDC patients is unclear. Therefore, this study aims to:

- Describe the proportion of SDC in all salivary gland carcinomas (SGC) before and after re - classification.
- Quantify the frequency of targeted therapy options (such as AR expression in more than 70% of tumor cells or HER2 - positive) in SDC patients.

### Methods
The study reviewed the clinical and pathological data of all SDC and ANOS patients treated in a tertiary medical center between 1996 and 2023. The expression of AR and HER2 was detected by immunohistochemistry (IHC), and its impact on treatment selection was analyzed.

### Results
- **Proportion of SDC**: During the study period, the proportion of SDC in all SGC increased from 7.1% - 11.5% in 2000 - 2015 to 15.4% - 18.1% in 2016 - 2023. After re - classification, the proportion of SDC increased significantly.
- **Targeted therapy options**: In 56.8% of SDC patients, AR was expressed in more than 70% of tumor cells, and 36.4% of patients were HER2 - positive. 70.5% of patients had at least one molecular target and could receive targeted therapy.

### Conclusions
The results of the study indicate that the incidence of SDC may be underestimated and has an upward trend in recent years. In addition, most SDC patients can determine targeted therapy options by detecting the expression of AR and HER2, which provides important guidance for clinical treatment.